Moderna

After reports of shortages involving Moderna’s updated COVID-19 booster shot, additional doses have begun to arrive at pharmacies nationwide, and more are expected soon.

The CDC voted Thursday to recommend updated versions of both the Pfizer and Moderna coronavirus vaccine boosters, paving way for a widespread rollout as early as next week.

The patent infringement lawsuits were filed in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany, according to a news release.

Moderna sued Pfizer and its German partner BioNTech on Friday, alleging that the two companies copied Moderna’s technology in developing their COVID-19 vaccine Comirnaty. Moderna said in a news release that Pfizer and BioNTech infringed on patents filed between 2010 and 2016 covering its mRNA technology, which Moderna used to develop its own COVID-19 vaccine, Spikevax.

Moderna said Tuesday it had asked the Food and Drug Administration to authorize an updated version of its Covid booster shot.

A new COVID vaccine will now be available in the U.S. after health officials recommended it Tuesday.

The Biden administration says it has reached an agreement with Moderna to buy 66 million doses of the company’s next generation of COVID-19 vaccine targeting the highly transmissible omicron variant.

A new COVID vaccine will now be available in the U.S. after health officials recommended it Tuesday.

The CDC has recommended the Novavax COVID-10 vaccine for adults ages 18 and up, providing more options and flexibility for the public.

The U.S. is getting another COVID-19 vaccine choice as the Food and Drug Administration on Wednesday cleared Novavax shots for adults.

Americans may soon get a new COVID-19 vaccine option — shots made with a more tried-and-true technology than today’s versions. Novavax received approval from the Food and Drug Administration for its COVID-19 vaccine Wednesday.

The FDA must still decide whether to take the recommendations and approve the COVID-19 vaccine for kids between six months and 5 years old.

COVID-19 shots for U.S. infants, toddlers and preschoolers moved a step closer Wednesday.

A government advisory panel has endorsed a second brand of COVID-19 vaccine for school-age children and teens. The expert panel agreed Tuesday that the vaccine made by Moderna is safe and effective enough to give to U.S. kids ages 6 to 17. A vaccine made by Pfizer has been available since last year for those ages. The Food and Drug...

Americans may soon get a new COVID-19 vaccine option — shots made with a more tried-and-true technology than today’s versions.

Moderna submitted data to the Food and Drug Administration that it hopes will prove two low-dose shots can protect children under the age of 6.

Moderna on Thursday asked U.S. regulators to authorize low doses of its COVID-19 vaccine for children younger than 6, a long-awaited move toward potentially opening shots for millions of tots by summer.

The U.S. could soon have a new COVID vaccine on the market but this one will be different from the others.

A 50-microgram dose of Moderna’s new vaccine doubled the antibodies against the omicron variant six months after administration.

Many Americans can now get a second COVID-19 booster, but it’s hard to tell who really needs another shot right now and who could wait.